TD Cowen Downgrades The Beauty Health Company (SKIN) to Market Perform

The Beauty Health Company (SKIN) plunges on Q3 miss as problems persist

The Beauty Health Company (NASDAQ: SKIN) shares plummeted more than 50% in premarket trading after the company missed consensus third-quarter estimates by a wide margin when it reported after the close on Monday.

The company reported a Q3 loss per share of $0.56, $0.63 worse than the analyst estimate of a profit of $0.07 per share. Meanwhile, revenue for the quarter came in at $97.4 million versus the consensus estimate of $116.23 million.

SKIN, home to flagship brand Hydrafacial, also revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million, its fiscal year... More

Piper Sandler Downgrades The Beauty Health Company (SKIN) to Underweight, 'Too Messy and Too Uncertain'

(Updated - November 14, 2023 4:28 AM EST)

Piper Sandler analyst Korinne Wolfmeyer downgraded The Beauty Health Company (NASDAQ: SKIN) from Overweight to Underweight with a price target of $2.00 (from $12.00).

The analyst comments "We're downgrading SKIN to Underweight from Overweight, a double-downgrade we only... More

JPMorgan Downgrades The Beauty Health Company (SKIN) to Underweight, 'hampered by execution challenges'

(Updated - November 14, 2023 4:33 AM EST)

JPMorgan analyst Allen Gong downgraded The Beauty Health Company (NASDAQ: SKIN) from Neutral to Underweight.

The analyst comments "We think investors were prepared for a softer quarter from BeautyHealth given the aesthetic prints weve seen to date; however, theres clearly more to unpack from a... More

Canaccord Downgrades The Beauty Health Company (SKIN) to Hold, 'lack of visibility of SKIN returning to growth plan'

(Updated - November 14, 2023 4:32 AM EST)

Canaccord Genuity analyst Susan Anderson downgraded The Beauty Health Company (NASDAQ: SKIN) from Buy to Hold with a price target of $2.50 (from $10.00).

The analyst comments "On 11/13 after the close, SKIN (Hold, $2.50 PT) reported disappointing 3Q results along with CEO Andrew Stanleick departing. Results were negatively impacted by continued challenges with the earlier versions of the Syndeo system leading to management marking all 1.0 and... More

The Beauty Health Company (SKIN) Misses Q3 EPS by 63c; lowers guidance

The Beauty Health Company (NASDAQ: SKIN) reported Q3 EPS of ($0.56), $0.63 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $97.4 million versus the consensus estimate of $116.23 million.

GUIDANCE:

The Beauty Health Company sees FY2023 revenue of $385-400... More

The Beauty Health Company's (SKIN) President and CEO to Depart

The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced that Andrew Stanleick will depart the Company as President & Chief Executive Officer and relinquish his Board seat, effective November 19, 2023. Current BeautyHealth Director Marla Beck will serve as Interim Chief Executive Officer while the Companys Board of Directors completes a formal search for a new CEO.

On behalf of the Board of Directors, I would like to thank Andrew for his leadership and commitment to BeautyHealth. He has been a passionate advocate for the Company, especially adding to its visibility within the... More